In diabetic rats with liver scarring, giving the peptide MOTS‑c or doing aerobic exercise both helped the liver heal. The peptide works by turning on a protective antioxidant pathway (Keap1‑Nrf2) and turning off a fibrosis‑promoting pathway (TGF‑β/Smad). These effects were seen in tissue stains, gene‑expression tests, and reduced oxidative stress in cells.
A lab study in rat bone‑marrow stem cells found that a tiny amount (1 µM) of the peptide MOTS‑c can boost the cells' transformation into bone‑forming cells, speeding up fracture healing in the dish. The effect works through a chain involving the proteins FOXF1 and TGF‑β. The work is still early‑stage and done only in cells, not people.
MOTS‑c is a tiny peptide produced by mitochondria that helps regulate glucose and fat metabolism, supports mitochondrial health, and lowers inflammation. Researchers think it might act like an exercise mimetic and could protect against lung scarring (pulmonary fibrosis). This review summarizes the existing evidence and points to possible future drug targets, but it doesn’t give any concrete dosing or treatment plan.
Zhong. Peng P; Peng. Jianye J; Hu. Yewen Y; Zhang. Jun J; Shen. Caijie C
In mice that were forced to develop heart failure by tightening their aorta, giving the tiny protein MOTS‑c under the skin helped keep the heart working better, reduced inflammation and oxidative damage, and turned on a protective AMPK pathway. Similar protective effects were seen in heart cells in a dish.
Researchers found that the tiny protein MOTS‑c, which can turn on the energy‑sensor AMPK, helps liver cancer cells die when they are low on oxygen. It does this by boosting a gene called MEF2A, which then raises the levels of death‑receptor proteins (DR4 and DR5) that make the cancer cells vulnerable to a natural killer signal (TRAIL). In mice, giving MOTS‑c slowed tumor growth under hypoxic conditions.
In mice, the vitamin‑like supplement pyrroloquinoline quinone (PQQ) reduced lung damage caused by high‑dose radiation. It did this by boosting the levels of the tiny protein MOTS‑c, which helped keep mitochondria (the cell's power plants) working and lowered inflammation and cell death. When MOTS‑c was blocked, PQQ’s protective effects disappeared, showing the benefit depends on MOTS‑c.
Researchers measured a tiny protein called MOTS‑c in people with sleep apnea and found that lower levels are linked to worse breathing problems, higher body weight, and more insulin resistance, which are all risk factors for metabolic disease.
MOTS‑c is a tiny protein made by mitochondria that helps cells cope with stress. Early research shows it can protect eye cells that are damaged by oxidation, which is linked to aging‑related eye diseases like macular degeneration, diabetic retinopathy, and glaucoma. The review suggests that boosting MOTS‑c could become a new way to keep the retina healthy, but real‑world dosing or treatment plans haven’t been worked out yet.
Researchers found that people having a heart attack (STEMI) have much lower blood levels of the peptide MOTS‑C compared to healthy controls, and that low MOTS‑C can predict a dangerous “no‑reflow” situation after opening the blocked artery. The test could help doctors spot patients at risk, but there’s no evidence yet that taking MOTS‑C as a supplement will improve outcomes.
Wojciechowska. Małgorzata M; Pruszyńska-Oszmałek. Ewa E; Kołodziejski. Pawe&...
Researchers measured a hormone called MOTS‑c in pregnant women and found its levels go up in obesity and down in thyroid problems, with the mother’s level matching the baby’s. This shows MOTS‑c reflects metabolic health during pregnancy, but the study doesn’t give any dosing or treatment tips yet.
Researchers found that a mitochondrial peptide called MOTS‑c can boost memory in mice and protect against memory loss caused by Alzheimer‑related proteins or inflammation, but the plain peptide doesn’t get into the brain on its own. By attaching it to a special cell‑penetrating carrier, it can reach the brain and still improve memory. The effect depends on activating the AMPK pathway and reducing brain inflammation.
The study found that people with relapsing‑remitting multiple sclerosis have lower blood levels of a tiny protein called MOTS‑c, which is linked to how mitochondria manage metabolism. Higher MOTS‑c levels seemed to protect against MS, and the test could tell apart patients from healthy folks fairly well, but the research didn’t give any dosing or treatment advice.
Cuyàs. Elisabet E; Verdura. Sara S; Martin-Castillo. Begoña B; Menendez. Javier A JA
In a study of breast‑cancer patients, taking metformin for 24 weeks didn’t change the amount of the exercise‑like hormone MOTS‑c in the blood, even when combined with chemo and trastuzumab. The hormone levels also didn’t predict who would have a complete tumor response. This suggests metformin isn’t a reliable way to boost MOTS‑c.
The study found that people with acute coronary events (like heart attacks) have higher blood levels of the peptide MOTS‑c, and these levels rise together with markers of oxidative stress. High MOTS‑c can help predict who will have a heart attack or unstable angina, and in patients who already had a heart attack, the ratio of MOTS‑c to oxidative‑stress markers may forecast future serious heart problems.
Yuan. Jinghan J; Wang. Manda M; Pan. Yanrong Y; Liang. Min M; Fu. Yu Y; Duan. Yimei Y; Tang. Mi M; L...
In rats that exercised, giving the mitochondrial peptide MOTS‑c made the heart work more efficiently and pumped stronger, with a hint it might also help the heart relax better. This suggests the peptide could boost the heart benefits of training, but the study was only in animals and didn’t test doses or safety for people.
Che. N N; Qiu. W W; Wang. J-K JK; Sun. X-X XX; Xu. L-X LX; Liu. R R; Gu. L L
A lab study found that the peptide MOTS‑c can boost the production of type I collagen in human bone‑forming cells by activating the TGF‑β/SMAD signaling pathway, which could help improve bone strength and counter osteoporosis. The effect was seen at low micromolar concentrations and depended on the amount of peptide used.
A lab study looked at how the peptide MOTS‑c changes the behavior of isolated pancreatic islets from rats and pigs. It found that MOTS‑c lowers the amount of insulin and glucagon the cells release and makes the cells more viable, but the effects were not the same in the two species.
Iboleon-Jimenez. Andrea A; Sánchez-Quintero. María J MJ; Carmona-Segovia. Ada D M ADM; Soj...
People having a heart attack have lower levels of the mitochondrial peptide MOTS‑c (and the protein PGC‑1α) in their blood. The study found no difference between men and women, and it linked MOTS‑c levels to heart‑damage markers like troponin and to blood‑cell counts. These findings suggest MOTS‑c could be a useful signal of heart stress, but the research does not test any treatments.
Ran. Ning N; Lin. Caorui C; Leng. Ling L; Han. Gang G; Geng. Mengyuan M; Wu. Yingjie Y; Bittner. Sco...
In a mouse model of Duchenne muscular dystrophy, the mitochondria‑derived peptide MOTS‑c boosted the muscles' energy production and helped a gene‑editing drug (PMO) get into the muscle cells better, leading to more dystrophin protein and improved muscle function without obvious side effects.
A lab study found that the tiny peptide MOTS‑c can push rat bone‑marrow stem cells to become bone‑forming cells by turning on the TGF‑β/Smad signaling pathway. This boosted calcium deposits in the cells, a sign of stronger bone formation, and the effect disappeared when the key TGF‑β1 gene was blocked.